Cspc Pharmaceutical
Cspc Pharmaceutical Group Limited, commonly referred to as Cspc, is a leading player in the pharmaceutical industry, headquartered in Hong Kong. Established in 1997, the company has made significant strides in research and development, focusing on innovative drug formulations and high-quality generic medicines. With a strong presence in both domestic and international markets, Cspc operates extensively across Asia, Europe, and North America. Cspc's core offerings include a diverse range of prescription drugs, over-the-counter products, and active pharmaceutical ingredients (APIs). The company is particularly noted for its advancements in oncology, cardiovascular, and central nervous system therapies, setting it apart through its commitment to quality and efficacy. Recognised for its robust market position, Cspc has achieved numerous accolades, solidifying its reputation as a trusted name in healthcare.
DitchCarbon Score
How does Cspc Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Cspc Pharmaceutical's score of 27 is lower than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Cspc Pharmaceutical's reported carbon emissions
In 2023, Cspc Pharmaceutical, headquartered in Hong Kong, reported total carbon emissions of approximately 1,081,261,000 kg CO2e, comprising 663,224,000 kg CO2e from Scope 1 and 418,037,000 kg CO2e from Scope 2. This represents a notable reduction from 2021, where total emissions were about 1,181,000,000 kg CO2e, with Scope 1 at 580,318,000 kg CO2e and Scope 2 at 600,682,000 kg CO2e. The company has demonstrated a commitment to reducing its carbon footprint, although specific reduction targets or initiatives have not been disclosed. Cspc Pharmaceutical has consistently reported emissions data for Scope 1 and Scope 2, indicating a focus on direct and indirect emissions from its operations. The emissions intensity, measured as kg CO2e per unit of revenue, has shown a downward trend, reflecting efforts to improve operational efficiency. Overall, while Cspc Pharmaceutical has made strides in emissions reporting and reduction, further details on specific climate commitments or targets would enhance understanding of its long-term sustainability strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 231,562,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 892,873,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Cspc Pharmaceutical is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
